Premium
Use of anti‐CD20 antibody in the treatment of post‐transplant glomerulonephritis
Author(s) -
Damodar Amar,
Mustafa Reem,
Bhatnagar Jyotsna,
Panesar Mandip,
Gundroo Aijaz,
Zachariah Mareena,
Blessios George,
Tornatore Kathleen,
WeberShrikant Edit,
Venuto Rocco
Publication year - 2011
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2010.01245.x
Subject(s) - medicine , proteinuria , membranoproliferative glomerulonephritis , rituximab , glomerulonephritis , immunosuppression , renal function , gastroenterology , urology , focal segmental glomerulosclerosis , membranous nephropathy , calcineurin , mycophenolic acid , plasmapheresis , transplantation , immunology , kidney , antibody
Damodar A, Mustafa R, Bhatnagar J, Panesar M, Gundroo A, Zachariah M, Blessios G, Tornatore K, Weber‐Shrikant E, Venuto R. Use of anti‐CD20 antibody in the treatment of post‐transplant glomerulonephritis.
Clin Transplant 2011: 25: 375–379. © 2010 John Wiley & Sons A/S. Abstract: Post‐transplant glomerulonephritis (PTGN) accounts for 4–10% of late graft loss. Six consecutive patients who developed PTGN 3–72 months post‐transplant presented to our center with deteriorating kidney function and proteinuria. Three had focal segmental glomerulosclerosis; one had membranoproliferative glomerulonephritis Type 1; one recurrent membranous nephropathy; and one recurrent immunoglobin A nephropathy. All six were treated with an aggressive immunosuppression regimen including rituximab, pulse steriods and/or maximization of mycophenolic acid and calcineurin inhibitor therapy. Four of the six patients received plasma exchange. The patients were followed for a minimum of nine months after treatment. Proteinuria decreased from 7.2 ± 4.4 to 1.4 ± 1.5 g (p = 0.04), while mean estimated glomerular filtration rate was 31.2 ± 13.1 and 42.5 ± 21.7 mL/min (p = 0.07) at nine months. No adverse events were noted. These observations suggest that immune modulating therapy may be of benefit in the treatment of PTGN.